HomeAI · summaries
Storia in 5 fonti
‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events
The Lp(a)HORIZON trial of pelacarsen, the first cardiovascular outcomes trial for an agent designed to lower lipoprotein(a), failed to achieve its primary outcome, Novartis announced. There are no therapies currently approved to lower Lp(a), high levels of which occur in about one in five people and are associated with elevated risk for CV events. Lp(a) levels are mostly genetically
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for…
- ·
healio.com
‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events
The Lp(a)HORIZON trial of pelacarsen, the first cardiovascular outcomes trial for an agent designed to lower lipoprotein(a), failed to achieve its primary outcome, Novartis…
